Autoimmunity in Type 1 Diabetes: A Pathophysiology Snapshot
T1D is an autoimmune disease whereby autoreactive T-cells drive progressive beta-cell damage and destruction, ultimately leading to insulin deficiency, dysglycemia, and hyperglycemia.
The number, type, and titer of islet autoantibodies detected in T1D screening tests provide valuable information about potential progression to clinical T1D.
Monitoring Individuals with T1D Islet Autoantibodies: Consensus Guidance
Expert consensus on monitoring individuals with T1D islet autoantibodies: detection, monitoring frequency, and psychosocial support for managing autoimmune T1D.
BR1DGE is a non-promotional global medical education program designed to advance understanding around presymptomatic type 1 diabetes and is provided by Sanofi.
This website is intended only for use by healthcare professionals in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, India, Ireland, Israel, Italy, Japan, Kingdom of Saudi Arabia, Kuwait, Luxembourg, Mexico, Norway, Portugal, Qatar, Russian Federation, Spain, Sweden, The Netherlands, The United Arab Emirates, and The United Kingdom (UK).
Note: Healthcare professionals from Ireland or The UK must click the second link below to be redirected to the local website.
Are you a healthcare professional from one of the countries listed above?
You are now being redirected to a third-party website.
You are now being redirected to a third-party website.
You are about to leave the Sanofi-sponsored BR1DGE website and enter a third-party website. This link is provided as a service and does not imply endorsement by Sanofi of the information contained on the third-party website. Sanofi is not responsible for the content, views, or privacy policies of this third-party site.
.svg)
